Free Trial
→ The most dangerous moment in a financial crisis (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CTSO

Cytosorbents Q3 2026 Earnings Date & Estimates

Cytosorbents logo
$4.54 +0.14 (+3.18%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$4.62 +0.09 (+1.87%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytosorbents is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cytosorbents in Q3 2026

Cytosorbents is expected to post earnings of -$0.90 per share on revenue of $9.90 million. In the same quarter a year earlier Cytosorbents reported -$0.80 per share on revenue of $9.49 million. Cytosorbents last reported on August 6, 2026, posting -$0.07 per share and beating the -$0.80 consensus estimate. Cytosorbents has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.90
Expected Revenue
$9.90 million
Prior-Year EPS
-$0.80
Prior-Year Revenue
$9.49 million
Expected Revenue Growth
+4.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Beat by +$0.73)
Last Quarter Revenue
$9.63 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Cytosorbents Q3 2026 Earnings FAQ

Cytosorbents (NASDAQ:CTSO) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Cytosorbents' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cytosorbents to post earnings of -$0.90 per share for Q3 2026.

The consensus revenue estimate for Cytosorbents is $9.90 million for Q3 2026.

Cytosorbents Earnings Headlines

Cytosorbents (CTSO) Set to Release Quarterly Earnings on Tuesday
October 31 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31169234
CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
October 29 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-to-report-third-quarter-2026-financial-results-and-recent-business-highlights-302923517.html
Why Gerardo Del Real says wait before buying uranium stocks
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
November 1 at 1:00 AM  |  Digest Publishing (Ad)
Cytosorbents (NASDAQ:CTSO) Research Coverage Started at WBB Securities
October 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151948
Cytosorbents consensus price target lowered by 26.67% to $35.53
October 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/cytosorbents-consensus-price-target-lowered-by-26-67-to-35-53/ar-AA2fVoRn
CTSO.O - | Stock Price & Latest News | Reuters
October 20, 2026  |  reuters.comhttps://www.reuters.com/jp/markets/companies/CTSO.O/all-listings
See More Cytosorbents Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email.

About Cytosorbents

Cytosorbents (NASDAQ:CTSO) is a medical device and healthcare company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent materials that can bind and remove cytokines, inflammatory mediators, drugs, and other molecules during extracorporeal blood treatment.

The company’s principal product is CytoSorb, an extracorporeal cytokine adsorber used in critical care and cardiac surgery applications. CytoSorb is designed to help manage excessive inflammation associated with conditions such as sepsis, shock, and other serious medical conditions. CytoSorbents also develops products for additional applications, including DrugSorb-ATR for removing certain antiplatelet drugs during or around cardiac surgery, and VetResQ for veterinary blood purification.

CytoSorbents markets its products internationally through direct sales and distribution partnerships. CytoSorb is approved for sale in the European Union and various other countries, while regulatory status differs by product and geography. The company is headquartered in Princeton, New Jersey, and is led by President and Chief Executive Officer Phillip Chan.

View Cytosorbents Profile
Earnings Tools